Stance Capital LLC Buys Shares of 6,801 AbbVie Inc. $ABBV

Stance Capital LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,801 shares of the company’s stock, valued at approximately $1,262,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Marshall & Sullivan Inc. WA purchased a new position in AbbVie in the 2nd quarter valued at approximately $25,000. TD Capital Management LLC raised its stake in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC acquired a new position in AbbVie during the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wells Fargo & Company lifted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Piper Sandler reiterated an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. BMO Capital Markets raised their price objective on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Finally, Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Stock Down 0.2%

Shares of NYSE:ABBV opened at $223.45 on Monday. The firm has a 50 day simple moving average of $227.25 and a 200-day simple moving average of $209.95. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $394.92 billion, a PE ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the business earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.